Amplification mechanisms of inflammation: paracrine stimulation of arachidonic acid mobilization by secreted phospholipase A2 is regulated by cytosolic phospholipase A2-derived hydroperoxyeicosatetraenoic acid.
In macrophages and other major immunoinflammatory cells, two phospholipase A(2) (PLA(2)) enzymes act in concert to mobilize arachidonic acid (AA) for immediate PG synthesis, namely group IV cytosolic phospholipase A(2) (cPLA(2)) and a secreted phospholipase A(2) (sPLA(2)). In this study, the molecular mechanism underlying cross-talk between the two PLA(2)s during paracrine signaling has been investigated. U937 macrophage-like cells respond to Con A by releasing AA in a cPLA(2)-dependent manner, and addition of exogenous group V sPLA(2) to the activated cells increases the release. This sPLA(2) effect is abolished if the cells are pretreated with cPLA(2) inhibitors, but is restored by adding exogenous free AA. Inhibitors of cyclooxygenase and 5-lipoxygenase have no effect on the response to sPLA(2). In contrast, ebselen strongly blocks it. Reconstitution experiments conducted in pyrrophenone-treated cells to abolish cPLA(2) activity reveal that 12- and 15-hydroperoxyeicosatetraenoic acid (HPETE) are able to restore the sPLA(2) response to levels found in cells displaying normal cPLA(2) activity. Moreover, 12- and 15-HPETE are able to enhance sPLA(2) activity in vitro, using a natural membrane assay. Neither of these effects is mimicked by 12- or 15-hydroxyeicosatetraenoic acid, indicating that the hydroperoxy group of HPETE is responsible for its biological activity. Collectively, these results establish a role for 12/15-HPETE as an endogenous activator of sPLA(2)-mediated phospholipolysis during paracrine stimulation of macrophages and identify the mechanism that connects sPLA(2) with cPLA(2) for a full AA mobilization response.
Balboa
María A
MA
Institute of Molecular Biology and Genetics, University of Valladolid School of Medicine, Valladolid, Spain.
Pérez
Rebeca
R
Balsinde
Jesús
J
D016718:Arachidonic Acid / Q000378:metabolism*; D003208:Concanavalin A / Q000494:pharmacology; D003600:Cytosol / Q000201:enzymology* / Q000378:metabolism; D004789:Enzyme Activation / Q000502:physiology; D054505:Group V Phospholipases A2; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000502:physiology*; D007249:Inflammation / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D015289:Leukotrienes / Q000096:biosynthesis / Q000502:physiology; D008054:Lipid Peroxides / Q000096:biosynthesis / Q000502:physiology; D008262:Macrophage Activation / Q000187:drug effects / Q000502:physiology; D008264:Macrophages / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D019899:Paracrine Communication / Q000502:physiology*; D010741:Phospholipases A / Q000378:metabolism* / Q000494:pharmacology / Q000502:physiology*; D054467:Phospholipases A2; D020298:U937 Cells; D015854:Up-Regulation / Q000502:physiology
D006893:Hydroxyeicosatetraenoic Acids; D015289:Leukotrienes; D008054:Lipid Peroxides; D003208:Concanavalin A; D016718:Arachidonic Acid; C021201:12-HPETE; C025086:15-hydroperoxy-5,8,11,13-eicosatetraenoic acid; D010741:Phospholipases A; D054505:Group V Phospholipases A2; C516299:PLA2G5 protein, human; D054467:Phospholipases A2